Seres Therapeutics First Quarter Financial Results and Clinical Pipeline Progress
Highlights Four significant microbiome program milestones expected during 2020, including readouts from two late-stage development programs SER-287 Fast Track designation obtained for active mild-to-moderate ulcerative colitis; Phase 2b study enrollment expected to be completed by […]